Drugs

Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible

Retrieved on: 
Thursday, June 27, 2019
Drugs, Medicine, Clinical medicine, Orphan drugs, Monoclonal antibodies, Immunosuppressants, Aromatic amines, RTT, Daratumumab, Lenalidomide, Multiple myeloma, Pomalidomide

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Key Points: 
  • A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
  • Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma.
  • 15Janssen Biotech, Inc. "DARZALEX (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies."
  • "Janssen Announces DARZALEX (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible."

Biosimilars Market: US Payer Insights Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 27, 2019
Health, Biotechnology, Biotechnology, Biosimilar, Drugs

The "Biosimilars: US Payer Insights (2019)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilars: US Payer Insights (2019)" report has been added to ResearchAndMarkets.com's offering.
  • How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma?
  • While payers remain upbeat about biosimilars they are looking to pharma to deliver the evidence of safety and utility to educate and support a cautious clinical community.
  • To really understand how US payers see the biosimilar market playing out turn to Biosimilars: US Payer Insights (2019).

Green Gorilla Launches USDA NOP Certified Organic Full-Spectrum 2400mg Hemp CBD Oil for Humans, Pets and Horses

Retrieved on: 
Thursday, June 27, 2019
Specialty, Convenience store, Alternative medicine, Health, Agriculture, Retail, Natural Resources, Drugs, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Hemp, Organ systems, CBD, Draft:Cbdmd

Green Gorilla, a leading manufacturer and brand of certified organic hemp cannabidiol (CBD) products, launched three new full-spectrum hemp CBD oils that are USDA NOP Certified Organic for humans, pets and horses.

Key Points: 
  • Green Gorilla, a leading manufacturer and brand of certified organic hemp cannabidiol (CBD) products, launched three new full-spectrum hemp CBD oils that are USDA NOP Certified Organic for humans, pets and horses.
  • Green Gorilla full-spectrum USDA NOP Certified Organic hemp CBD oil is non-GMO, vegan, paleo, low-carb, gluten-free and sugar-free.
  • Ingredients in the product are USDA NOP Certified Organic extra-virgin olive oil, phytocannabinoid rich organic hemp extract (aerial parts), turmeric root extract, rosemary leaf extract and lecithin.
  • Green Gorilla is a vertically integrated global brand in the hemp and cannabis industries and a leading manufacturer of certified organic hemp-derived cannabidiol (CBD) products such as pure CBD oil, full-spectrum CBD oil, CBD topicals, CBD gummies, CBD for pets and CBD for horses.

Medical Marijuana, Inc. Issues Letter to Shareholders

Retrieved on: 
Thursday, June 27, 2019
Medicine, Health sciences, Drugs, Herbalism, Medicinal plants, Cannabis in California, Medical Marijuana, Inc., Hemp, Cannabidiol, Cannabis, Medical cannabis, Industrial Hemp Farming Act

To read the Letter to Shareholders in full, please visit: https://investors.medicalmarijuanainc.com/medical-marijuana-shareholder-... .

Key Points: 
  • To read the Letter to Shareholders in full, please visit: https://investors.medicalmarijuanainc.com/medical-marijuana-shareholder-... .
  • Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop .
  • These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets.

Medical Cannabis Evidence Portal Launched by the Academy of Medical Cannabis

Retrieved on: 
Thursday, June 27, 2019
Medicine, Drugs, Cannabis smoking, Herbalism, Medicinal plants, Antiemetics, Appetite stimulants, Medical cannabis, Cannabis, Effects of cannabis, Tetrahydrocannabinol, Medical cannabis in the United States

LONDON, June 27, 2019 /PRNewswire/ -- A new, comprehensive and free to use evidence portal providing healthcare professionals with access to the latest peer-reviewed scientific research about medical cannabis has launched.

Key Points: 
  • LONDON, June 27, 2019 /PRNewswire/ -- A new, comprehensive and free to use evidence portal providing healthcare professionals with access to the latest peer-reviewed scientific research about medical cannabis has launched.
  • The Academy of Medical Cannabis (taomc.org), an internationally-recognised online educational platform to support the safe and effective use of medical cannabis, has developed the first global medical cannabis evidence repository to focus on human studies.
  • The Academy of Medical Cannabis is an internationally-recognised online educational platform to support the safe and effective use of medical cannabis.
  • Founded by leading medical cannabis expert, Professor Mike Barnes, the Academy provides world-leading professional development and specialised learning.

NYU Langone Health Launches New Center to Study the Drivers and Consequences of the National Opioid Epidemic

Retrieved on: 
Thursday, June 27, 2019
Psychoactive drugs, RTT, Morphine, Medical emergencies, Opioids, Drugs, Substance abuse, Drug overdose, Heroin, Langone

The new center, led by Magdalena Cerd, DrPH , associate professor in the Department of Population Health at NYU Langone, uses a multidisciplinary approach to develop scientific evidence on the nature, causes, and consequences of the opioid overdose epidemic.

Key Points: 
  • The new center, led by Magdalena Cerd, DrPH , associate professor in the Department of Population Health at NYU Langone, uses a multidisciplinary approach to develop scientific evidence on the nature, causes, and consequences of the opioid overdose epidemic.
  • "This center will be a phenomenal national resource to address these issues here in New York and across the country."
  • The proportion of deaths attributable to opioid overdose rose by nearly 300 percent from 2001 to 2016 and continue to rise.
  • Watch a video of Dr. Magdalena Cerd outline the mission and goals of the Center for Opioid Epidemiology and Policy: https://bcove.video/2KEuzuN

Double Chamber Prefilled Syringes Market Poised to Register 9% CAGR Through 2029 - PMR

Retrieved on: 
Thursday, June 27, 2019
Medical equipment, Psychoactive drugs, Drug paraphernalia, Syringe, Pharmacology, Drugs, Heroin

High convenience associated with the usage of double chamber prefilled syringes is driving their adoption among end users, which is boosting the demand for double chamber prefilled syringes.

Key Points: 
  • High convenience associated with the usage of double chamber prefilled syringes is driving their adoption among end users, which is boosting the demand for double chamber prefilled syringes.
  • This is one of the leading factors that are significantly contributing to the growth of the double chamber prefilled syringes market.
  • The (5 mL) the double chamber prefilled syringes segment, thereby accounting for the second highest revenue generating product segment.
  • India is estimated to be among the rapidly growing emerging markets in the global double chamber prefilled syringes market, and is projected to grow at aCAGRof more than10%during the forecast period of 2019-2029.The double chamber prefilled syringes market report tracks some of the key companies operating in double chamber prefilled syringes market, such as

Double Chamber Prefilled Syringes Market Poised to Register 9% CAGR Through 2029 - PMR

Retrieved on: 
Thursday, June 27, 2019
Medical equipment, Psychoactive drugs, Drug paraphernalia, Syringe, Pharmacology, Drugs, Heroin

High convenience associated with the usage of double chamber prefilled syringes is driving their adoption among end users, which is boosting the demand for double chamber prefilled syringes.

Key Points: 
  • High convenience associated with the usage of double chamber prefilled syringes is driving their adoption among end users, which is boosting the demand for double chamber prefilled syringes.
  • This is one of the leading factors that are significantly contributing to the growth of the double chamber prefilled syringes market.
  • The (5 mL) the double chamber prefilled syringes segment, thereby accounting for the second highest revenue generating product segment.
  • India is estimated to be among the rapidly growing emerging markets in the global double chamber prefilled syringes market, and is projected to grow at aCAGRof more than10%during the forecast period of 2019-2029.The double chamber prefilled syringes market report tracks some of the key companies operating in double chamber prefilled syringes market, such as

NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)

Retrieved on: 
Thursday, June 27, 2019
Drugs, RTT, Clinical medicine, Medicine, Specialty drugs, Cancer treatments, Genentech, Orphan drugs, Biosimilar, Adalimumab, Bevacizumab, Rituximab

This NDA by Innovent is the fourth that has been accepted by the NMPA following Tyvyt (sintilimab injection), IBI303 (a biosimilar product candidate of adalimumab injection, granted priority review status) and IBI305 (a biosimilar product candidate of bevacizumab injection, granted priority review status).

Key Points: 
  • This NDA by Innovent is the fourth that has been accepted by the NMPA following Tyvyt (sintilimab injection), IBI303 (a biosimilar product candidate of adalimumab injection, granted priority review status) and IBI305 (a biosimilar product candidate of bevacizumab injection, granted priority review status).
  • Despite the high unmet demand for effective cancer therapies in China, the adoption rate of rituximab is relatively low due to low affordability.The biosimilar product candidate of rituximab, IBI301, is expected to offer a high-quality and affordable alternative to patients in China.
  • Based on the high-quality clinical data, the NDA of IBI301 has been accepted by NMPA.
  • We hope that the drug can be launched soon to benefit more lymphoma patients," said Professor Jun Zhu, Beijing Cancer Hospital.

The United States Female Contraception Market 2014-2024 - Pipeline; Epidemiology; Drugs, Drug Sales & Drugs Market Share; Market Valuations; and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Medical devices, Women, Consumer, Health, Drugs, Sex hormones, Progestogens, Hormonal contraception, Pregnanes, Alcohols, RTT, Birth control, Medroxyprogesterone acetate, Male contraceptive

This latest research provides comprehensive insights into Female Contraception pipeline products, Female Contraception epidemiology, Female Contraception market valuations and forecast, Female Contraception drugs sales and competitive landscape in the US.

Key Points: 
  • This latest research provides comprehensive insights into Female Contraception pipeline products, Female Contraception epidemiology, Female Contraception market valuations and forecast, Female Contraception drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Female Contraception treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Female Contraception pipeline: Find out the products in clinical trials for the treatment of Female Contraception by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Female Contraception drugs: Identify key products marketed and prescribed for Female Contraception in the US, including trade name, molecule name, and company
    Female Contraception market valuations: Find out the market size for Female Contraception drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Female Contraception drugs market share: Find out the market shares for key Female Contraception drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Female Contraception products